- Company
- “The framework to list ultra-expensive new drugs exists"
- by Eo, Yun-Ho Apr 14, 2021 06:07am
- We are living in an era where a single injection may completely cure cancer. The catch is that the 'single dose' would cost 500 million won. Such ultra-expensive advanced new drugs are not an item of our dreams &8211; it is already within our reach. In addition to the CAR-T (Chimeric Antigen Receptor T cells) therapy Kymriah (tisagenlecleuce
- Company
- Generic for Eliquis, stop selling after supreme court loss
- by Kim, Jin-Gu Apr 14, 2021 06:07am
- Eliquis (Apixaban)’s generic companies stop selling one after another. This is a strategy after the Supreme Court ruled in favor of the original company BMS in the Eliquis patent dispute. This is a measure to reduce the risk even a little in preparation for future lawsuits for claiming damages. According to the pharmaceutical industry
- Company
- Geo-Young is interested in distributing botulinum products
- by Nho, Byung Chul Apr 14, 2021 06:06am
- Geo-Young and Zuellig entered the competition for the storage and distribution of Xeomin of Multz, Germany, which is the best importer of botulinum toxin products. According to the pharmaceutical industry on the 9th, Multz is conducting a competitive bidding ahead of the expiration of the contract with Zuellig, an existing Xeomin storage
- Company
- MNC employees earn ₩91 million on average
- by An, Kyung-Jin Apr 13, 2021 05:19pm
- GSK Consumer Healthcare Korea employees received on average a salary of 150 million won last year. Employees at GSK Korea, Boehringer Ingelheim Korea, Sanofi Pasteur, Viatris Korea, Kyowa Kirin Korea, Galderma Korea, Pfizer Korea, and Abbvie Korea also received an average salary of over 100 million won. According to the Financial Super
- Company
- Lilly spent ₩9.7 billion in severance pay last year
- by An, Kyung-Jin Apr 13, 2021 05:46am
- Lilly Korea spent nearly &8361;10 billion last year as employee severance pay. At the end of last year, the Hope Retirement Program (ERP) was launched for all employees of the sales department, and the amount of severance pay has jumped more than five times from the previous year. According to Lilly Korea's audit report submitted to the F
- Company
- Yuhan distributed gold rings to all employees
- by Kim, Jin-Gu Apr 12, 2021 05:55am
- Yuhan recently handed out gold rings to former employees, showing Leclaza (Lazertinib)'s commitment to success. According to the industry on the 11th, Yuhan provided a gold ring with LECLAZA to all employees at the end of last February. It was only a month after receiving Conditional Marketing Authorization (CMA) as the 31st Korean drug on
- Company
- Price hike of ‘Rotarix’ after ‘RotaTeq’ adds burden
- by Apr 12, 2021 05:54am
- The price of rotavirus vaccines for newborns is expected to increase altogether, with GSK also deciding to increase its supply price of ‘Rotarix’ after MSD’s price hike on ‘RotaTeq.’ Kwang Dong Pharmaceutical, the company in charge of the domestic supply of GSK’s Rotarix, recently sent a notice to clinics and hospitals on the de
- Company
- Local companies in panic over ‘Eliquis’ patent suit result
- by Kim, Jin-Gu Apr 9, 2021 05:56am
- The winner and loser of the long patent suit were reversed in the end. After losing the first and second trial, BMS finally got the upper hand in the fight with the generic manufacturers with a favorable ruling by the supreme court. On the other side, the generic companies are in hot water due to the unexpected result. In addition to im
- Company
- Tagrisso’s 1st-line reimbursement rejected once again
- by Eo, Yun-Ho Apr 9, 2021 05:55am
- With ‘Tagrisso’ once again failing to expand its reimbursement, it seems that it may take a while for 3rd generation EGFR TKIs to be prescribed as 1st-line in Korea. According to industry sources, the Cancer Disease Review Committee of the Health Insurance Review and Assessment Service (HIRA) decided it was inappropriate to expand the
- Company
- Qsimia's sales exceeded ₩200 billion
- by An, Kyung-Jin Apr 9, 2021 05:55am
- Alvogen Korea surpassed &8361;200 billion in annual sales for the first time since its launch in Korea. Qsymia, an obesity treatment drug released at the beginning of last year, and the obesity treatment Qsymia, which was released earlier last year, produced the largest sales. According to the Financial Supervisory Service on the 7th, Alvoge
